Parameter
| Biomarker | PTEN Mut | Full name | PTEN Mutation | Molecular Type | Gene Mutation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, Prediction |
| Disease | Glioblastoma | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue (NGS, Sanger Sequencing) | ||
| Pathobiological Mechanisms | Tumor suppressor gene inactivation activates the PI3K/AKT/mTOR pathway, enhancing tumor invasiveness and chemotherapy resistance. | ||||
| Clinical Availability Status | Under clinical validation | ||||
| Notes and Dynamics | Mutant patients are sensitive to mTOR inhibitors (everolimus), which can reverse partial chemotherapy resistance. | ||||